Immune Design Corp. (IMDZ) Expected to Post Quarterly Sales of $620,000.00
Brokerages forecast that Immune Design Corp. (NASDAQ:IMDZ) will post sales of $620,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Immune Design Corp.’s earnings, with estimates ranging from $400,000.00 to $840,000.00. Immune Design Corp. posted sales of $8.21 million during the same quarter last year, which suggests a negative year over year growth rate of 92.4%. The business is scheduled to issue its next earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Immune Design Corp. will report full year sales of $620,000.00 for the current year, with estimates ranging from $7.00 million to $11.00 million. For the next year, analysts expect that the company will post sales of $16.54 million per share, with estimates ranging from $15.08 million to $18.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Immune Design Corp..
Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.50 million.
IMDZ has been the subject of several research analyst reports. ValuEngine raised shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $18.00 target price on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Tuesday, July 18th. BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Finally, Royal Bank Of Canada initiated coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $16.33.
In related news, major shareholder Leo Guthart bought 10,000 shares of the company’s stock in a transaction dated Monday, September 18th. The stock was purchased at an average cost of $9.70 per share, with a total value of $97,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lewis W. Coleman bought 8,000 shares of the company’s stock in a transaction dated Friday, July 7th. The stock was bought at an average cost of $9.27 per share, with a total value of $74,160.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at approximately $370,800. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 40,000 shares of company stock valued at $369,760. Corporate insiders own 20.70% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Wells Fargo & Company MN increased its stake in shares of Immune Design Corp. by 46.5% in the 1st quarter. Wells Fargo & Company MN now owns 148,887 shares of the biotechnology company’s stock worth $1,012,000 after acquiring an additional 47,266 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Immune Design Corp. in the 1st quarter worth about $183,000. Victory Capital Management Inc. increased its stake in shares of Immune Design Corp. by 11.6% in the 1st quarter. Victory Capital Management Inc. now owns 1,937,554 shares of the biotechnology company’s stock worth $13,175,000 after acquiring an additional 202,149 shares in the last quarter. FMR LLC increased its stake in shares of Immune Design Corp. by 0.4% in the 1st quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock worth $3,027,000 after acquiring an additional 1,699 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Immune Design Corp. by 18.9% in the 1st quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock worth $310,000 after acquiring an additional 7,236 shares in the last quarter. 51.46% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/immune-design-corp-imdz-expected-to-post-quarterly-sales-of-620000-00/1608788.html.
Shares of Immune Design Corp. (NASDAQ IMDZ) opened at 10.85 on Thursday. The company’s market capitalization is $277.97 million. Immune Design Corp. has a 1-year low of $4.50 and a 1-year high of $13.05. The firm has a 50-day moving average of $9.82 and a 200 day moving average of $8.36.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.